CZ303607B6 - Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone - Google Patents
Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone Download PDFInfo
- Publication number
- CZ303607B6 CZ303607B6 CZ20110761A CZ2011761A CZ303607B6 CZ 303607 B6 CZ303607 B6 CZ 303607B6 CZ 20110761 A CZ20110761 A CZ 20110761A CZ 2011761 A CZ2011761 A CZ 2011761A CZ 303607 B6 CZ303607 B6 CZ 303607B6
- Authority
- CZ
- Czechia
- Prior art keywords
- codeine
- ccm
- formula
- strain
- medium
- Prior art date
Links
- 229960004126 codeine Drugs 0.000 title claims abstract description 47
- 241000589155 Agrobacterium tumefaciens Species 0.000 title claims abstract description 28
- 244000005700 microbiome Species 0.000 title claims abstract description 15
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical group C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims abstract description 88
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000006243 chemical reaction Methods 0.000 claims abstract description 40
- 239000002028 Biomass Substances 0.000 claims abstract description 16
- YPZPXTZKBNWUTF-QMVVXIJUSA-N (4r,4as,7s,7ar,12bs)-9-methoxy-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol Chemical compound O[C@H]([C@@H]1O2)C=C[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C YPZPXTZKBNWUTF-QMVVXIJUSA-N 0.000 claims abstract description 14
- YPZPXTZKBNWUTF-UHFFFAOYSA-N 14beta-Hydroxy-codein Natural products O1C2C(O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YPZPXTZKBNWUTF-UHFFFAOYSA-N 0.000 claims abstract description 14
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 claims abstract description 13
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930013930 alkaloid Natural products 0.000 claims abstract description 3
- 239000002609 medium Substances 0.000 claims description 32
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- 229960005181 morphine Drugs 0.000 claims description 15
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims description 13
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims description 13
- 229930003945 thebaine Natural products 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 230000000640 hydroxylating effect Effects 0.000 claims description 3
- 238000012366 Fed-batch cultivation Methods 0.000 claims description 2
- 239000012527 feed solution Substances 0.000 claims description 2
- 239000012526 feed medium Substances 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000033444 hydroxylation Effects 0.000 abstract description 8
- 238000005805 hydroxylation reaction Methods 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000036983 biotransformation Effects 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 240000001090 Papaver somniferum Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000008753 Papaver somniferum Nutrition 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WYMBHLXUDPDGQJ-BRJGLHKUSA-N (4r,4as,7s,7ar,12bs)-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol Chemical compound O([C@H]1[C@H](C=C[C@]23O)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WYMBHLXUDPDGQJ-BRJGLHKUSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002361 compost Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VFNHLTBRAFJQER-ISWURRPUSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(O)=CC=C1C4 VFNHLTBRAFJQER-ISWURRPUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- MFXFQKMUCYHPFQ-BKRJIHRRSA-N 6-monoacetylcodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC MFXFQKMUCYHPFQ-BKRJIHRRSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241000192652 Desmonostoc muscorum Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000187469 Mycobacterium neoaurum Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 235000011096 Papaver Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000042002 Trametes sanguinea Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- XYYVYLMBEZUESM-CMKMFDCUSA-N codeinone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XYYVYLMBEZUESM-CMKMFDCUSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- -1 hydroxy codeine Chemical compound 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007003 mineral medium Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- PFBSOANQDDTNGJ-YNHQPCIGSA-N morphinone Chemical compound O([C@H]1C(C=C[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O PFBSOANQDDTNGJ-YNHQPCIGSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- HKOIXWVRNLGFOR-KOFBORESSA-N norcodeine Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 HKOIXWVRNLGFOR-KOFBORESSA-N 0.000 description 1
- HKOIXWVRNLGFOR-UHFFFAOYSA-N norcodeine Natural products O1C2C(O)C=CC3C4CC5=CC=C(OC)C1=C5C23CCN4 HKOIXWVRNLGFOR-UHFFFAOYSA-N 0.000 description 1
- 229950004392 norcodeine Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/41—Rhizobium
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Oblast technikyTechnical field
Vynález se týká hydroxylace kodeinu vzorce 1, na 14-hydroxykodein vzorce 2 a 14-hydroxykodeinon vzorce 3 kmenem mikroorganismu Rhizobium radiobacter R89-1 CCM 7947. Při hydroxylaci vzniká převážně 14—hydroxykodein vzorce 2.The present invention relates to the hydroxylation of codeine of formula 1 to 14-hydroxycodeine of formula 2 and 14-hydroxycodeinone of formula 3 with a strain of Rhizobium radiobacter R89-1 CCM 7947.
ioio
Reakce poskytuje 100% konverzi kodeinu na 14-hydroxykodein vzorce 2 a 14-hydroxykodeinon vzorce 3 při počáteční koncentrací kodeinu 1,5 g/1, 90% při 3,0 g/1 a při počáteční koncentraci 6 g/1 je konverze 47 %.The reaction provides 100% conversion of codeine to 14-hydroxycodein of formula 2 and 14-hydroxycodeinone of formula 3 at an initial codeine concentration of 1.5 g / l, 90% at 3.0 g / l, and at an initial concentration of 6 g / l the conversion is 47% .
Dosavadní stav technikyBACKGROUND OF THE INVENTION
Kodein, morfin a thebain patří mezi přírodní alkaloidy, které jsou produkovány mákem setým (Papaver somruje rum). Zavedení hydroxyl skupiny do C-l 4 pozice morfin alkaloidové struktury je využíváno pro přípravu látek oxykodon, naloxon, oxymorfon a naltrexon, které se v medicíně používají jako analgetika, antitussiva a léky pro odvykání drogové a alkoholové závislosti. Nejpoužívanější výchozí surovinou pro chemickou výrobu těchto opiátů je thebain, minoritní kom25 ponenta v přírodním opiovém extraktu. Ten je konvertován oxidací (peroxykyselinou) na 14hydroxykodeinon (López, D, Quióoa, E., Riguera, R. 1994 Tetrahedron Lett., 31,5727-5730). Vzhledem k tomu, že kodein a morfin jsou mnohem dostupnější než thebain, jsou tedy perspektivními prekurzory pro přípravu 14-hydroxy opiátů. Popsané chemické metody vykazují nízké výtěžky, hromadění těžko separovatelných vedlejších produktů a nutnost použití nežádoucích těžkých kovů (Zhang, Q., Rich, J. O., Cotterill, C., Pantaleone D. P., Michels, P. C, 2005 J. Am. Chem. Soc. 127,7286-7287).Codeine, morphine and thebaine are natural alkaloids produced by poppy (Papaver somruje rum). Introduction of the hydroxyl group at the C-14 position of the morphine alkaloid structure is used for the preparation of oxycodone, naloxone, oxymorphone and naltrexone, which are used in medicine as analgesics, antitussives and drugs for drug and alcohol dependence cessation. The most commonly used starting material for the chemical production of these opiates is thebaine, a minor component of the natural opium extract. This is converted by oxidation (peroxyacid) to 14-hydroxycodeinone (Lopez, D, Quioo, E., Riguera, R. 1994 Tetrahedron Lett., 31,5727-5730). Since codeine and morphine are much more accessible than thebaine, they are therefore promising precursors for the preparation of 14-hydroxy opiates. The chemical methods described show low yields, the accumulation of hardly separable by-products and the necessity of using unwanted heavy metals (Zhang, Q., Rich, JO, Cotterill, C., Pantaleone DP, Michels, P. C., 2005 J. Am. Chem. Soc. 127,7286-7287).
Počátky zájmu o získání efektivnějších analgetik z přírodních opiátů pomocí biotransformací spadá do 1960 let. První práce popisující schopnost basidíomycety Trametes sanguinea transfor35 movat thebain pomocí allylic oxygenací a demetylací na 14-hydroxykodeinon a následnou redukcí na 14-hydroxykodein popsal Iizuka a kol. (Iizuka, K., Okuda, S., Aida, K., Asai, T., Tsuda, K., Yamada, M., Seki, 1. 1960 I. Chem. Pharm. Bull. 8, 1056-7 a Iizuka, K., Yamada, M., Suzuki, J., Seki, I., Aida, K., Okuda, S., Assay, T., Tsuda, K. 1962, Chem. Pharm. Bull. 10, 6770).The beginnings of interest in obtaining more effective analgesics from natural opiates through biotransformation date back to the 1960s. The first work describing the ability of the basidiomycetes Trametes sanguinea to transform thebaine by allylic oxygenation and demethylation to 14-hydroxycodeinone and subsequent reduction to 14-hydroxycodein was described by Iizuka et al. (Iizuka, K., Okuda, S., Aida, K., Asai, T., Tsuda, K., Yamada, M., Seki, 1, 1960 I. Chem. Pharm. Bull. 8, 1056-7, and Iizuka, K., Yamada, M., Suzuki, J., Seki, I., Aida, K., Okuda, S., Assay, T., Tsuda, K. 1962, Chem. Pharm. Bull. 10, 6770 ).
Tsuda, K. (1964, ϊ. A, M. Symposium on Microbiology No. 6, Institute of Appl. Microbiol., University of Tokyo, Tokyo, Japan) popsal u Trametes sanguinea (a dalších 120 kmenů basidiomycet z testovaných 1200 různých bakteriálních a plísňových kmenů) konverzi thebainu na 14-hydroxykodeinon a 14-hydroxykodein. Podobné výsledky byly publikovány v jiné nezávislé studii s plísní Trametes cinnabarina (Gróger, D and Schmauder, Η. P. 1969, Experentia 25, 95-96).Tsuda, K. (1964, AA, M. Symposium on Microbiology No. 6, Institute of Appl. Microbiol., University of Tokyo, Tokyo, Japan) described in Trametes sanguinea (and another 120 basidiomycetes strains from 1200 different bacterial strains tested). and fungal strains) converting thebaine to 14-hydroxycodeinone and 14-hydroxycodein. Similar results were published in another independent study with Trametes cinnabarina (Gröger, D and Schmauder, ma P. 1969, Experentia 25, 95-96).
- 1 CZ 303607 B6- 1 GB 303607 B6
Mikrobiální transformace morfiových alkaloidů byla rovněž popsána u bakteriálních kmenů. Liras, P. a Umbreit, W. W. (1975, Appl. Microbiok 30, 262-266) popsali konverzi morfinu na I4-hydroxymorfin klidovými buňkami Arthobacter sp.Microbial transformation of morphine alkaloids has also been described in bacterial strains. Liras, P. and Umbreit, W.W. (1975, Appl. Microbiok 30, 262-266) described the conversion of morphine to 14-hydroxymorphine by resting Arthobacter sp.
Nízká koncentrace 14-hydroxymorfínu, jako produktu biotransformace, byla také nalezena u Pseudomonas testosteronii. U tohoto kmene byly popsány a - a β-hydroxysteroid dehydrogenázy, které produkovaly morfinon a kodeinon z kóde inu nebo morfinu v přítomnosti NAD+ (Liras, P., Kasparian, S. S. Umbreit, W. W. 1975, Appl. Microbiol. 30, 650-656).Low concentrations of 14-hydroxymorphine as a biotransformation product have also been found in Pseudomonas testosteronii. In this strain, α- and β-hydroxysteroid dehydrogenases have been described which produced morphinone and codeinone from inine or morphine code in the presence of NAD + (Liras, P., Kasparian, SS Umbreit, WW 1975, Appl. Microbiol. 30, 650-656 ).
ioio
Také u rodu Bacillus sp. byla popsána transformace morfinu a kodeinu na 14-hydroxymorfinon a 14-hydroxykodeinon (Madyastha, Κ. M., Reddy, G. V. B. 1994, J. Chem. Soc. Perkin Trans. 1 (8),911-912).Also in Bacillus sp. the transformation of morphine and codeine into 14-hydroxymorphinone and 14-hydroxycodeinone has been described (Madyastha, M., Reddy, G.V. 1994, J. Chem. Soc. Perkin Trans. 1 (8), 911-912).
i5 Harder, P. A. a Kunz, D. A. (1989 United States Patent No. 4 798 792) patentovali bakteriální hydroxylaci kodeinu ajeho ve vodě rozpustné soli na 14—hydroxykodein kmeny rodu Streptomyces. Nejvyšší konverze vykazoval kmen Streptomyces griseus NRRL B8090. Při použití bohatého média obsahujícího sojovou mouku v průběhu 30 denní kultivace a pri počáteční koncentraci kodeinu 1 mM (0,29 mg/ml). Po 27 dnech bylo u tohoto kmene získáno 0,2 mM (63 mg/l) 14-OH kodeinu a 0,03 mM (8,55 mg/l) norkodeinu.Harder, P.A. and Kunz, D.A. (1989 United States Patent No. 4,798,792) patented bacterial hydroxylation of codeine and its water-soluble salts to 14-hydroxycodeine strains of the genus Streptomyces. Streptomyces griseus NRRL B8090 showed the highest conversion. Using a rich medium containing soy flour during a 30 day culture and at an initial codeine concentration of 1 mM (0.29 mg / ml). After 27 days, 0.2 mM (63 mg / l) of 14-OH codeine and 0.03 mM (8.55 mg / l) of norodeine were obtained in this strain.
Zhang, Q., Rich, J. O., Cotterill, I. C., Pantaleone, D. P., Michels, P. C. 2005, J. Am. Chem. Soc. 127, 7286-7287 popsali u Mycobacterium neoaurum (MTP650) schopnost hydroxy láce kodeinu na 14—hydroxykodein a mechanismus reakcí.Zhang, Q., Rich, J.O., Cotterill, I.C., Pantaleone, D.P., Michels, P.C. 2005, J. Am. Chem. Soc. 127, 7286-7287 described in Mycobacterium neoaurum (MTP650) the ability of hydroxy codeine to 14-hydroxycodeine and the mechanism of reactions.
Bikonverzi kodeinu na semi-syntetické deriváty opiátů (6-acetylkodein, oxykodon, norkodein, morfin) popsali u Nostoc muscorum Niknam a kol. (Nikam, S., Faramazi, M. A., Abdi, K., Yazdi, Μ. T., Amini, M., Rastegar, H. 2010, World J. Microbiol. Biotechnol. 26, 119-123). Derivát 14-OH kodein nebyl detekován. Optimální koncentrace kodeinu pro biotransformaci celýmiBiconversion of codeine to semi-synthetic opioid derivatives (6-acetyl codeine, oxycodone, norcodeine, morphine) has been described by Nostoc muscorum Niknam et al. (Nikam, S., Faramazi, M.A., Abdi, K., Yazdi, T. T., Amini, M., Rastegar, H. 2010, World J. Microbiol. Biotechnol. 26, 119-123). The 14-OH codeine derivative was not detected. Optimal codeine concentration for whole biotransformation
3« buňkami byla 0,5 až 1,0 mg/ml; deriváty byly identifikovány po konverzi v délce 5 až 10 dní.3 cells were 0.5 to 1.0 mg / ml; derivatives were identified after conversion for 5 to 10 days.
Wick, A., Wagner, M., Ternem, T. A. 2011, Environ. Sci. Technol. 46, 3374-3385 popsali transformační dráhy kodeinu aktivovaným kalem z čistírny za aerobních podmínek. Jednou z popsaných drah je hydroxylace kodeinu v C-l 4 pozici. Výchozí koncentrace kodeinu byla 5 mg/l.Wick, A., Wagner, M., Ternem, T. A. 2011, Environ. Sci. Technol. 46, 3374-3385 described codeine transformation pathways by activated sludge from a sewage treatment plant under aerobic conditions. One of the pathways described is the hydroxylation of codeine at the C-14 position. The initial codeine concentration was 5 mg / l.
V literatuře není popsána hydroxylace kodeinu 1 na 14-hydroxykodein 2 a 14-hydroxykodeinon 3 kmeny mikroorganismu rodu Rhizobium.There is no description in the literature of the hydroxylation of codeine 1 to 14-hydroxycodein 2 and 14-hydroxycodeinone 3 by strains of a microorganism of the genus Rhizobium.
Podstata vynálezuSUMMARY OF THE INVENTION
Podstatou vynálezu je nový kmen mikroorganismu Rhizobium radiobacter R89-1 CCM 7947, který je schopen hydroxylovat kodein vzorce 1 poloze 14The present invention provides a new strain of Rhizobium radiobacter R89-1 CCM 7947 which is capable of hydroxylating codeine of formula 1 at position 14
na 14-hydroxykodein vzorce 2 a 14-hydroxykodeinon vzorce 3to 14-hydroxycodein of formula 2 and 14-hydroxycodeinone of formula 3
- 2 CZ 303607 B6- 2 GB 303607 B6
se stoprocentní konverzí kodeinu vzorce 1. Při hydroxylaci vzniká převážně 14—hydroxykodein.The hydroxylation produces predominantly 14-hydroxycodeine.
Podrobný popis vynálezuDETAILED DESCRIPTION OF THE INVENTION
Kmen Rhizobium radiobacter R89-1 CCM 7947 byl získán rozsáhlým screeningem více než 2000 sbírkových a z přírody izolovaných mikroorganismů (kvasinky, plísně a bakterie). Screeningem byly získány dva bakteriální kmeny, vykazující dané vlastnosti. Pouze kmen R89-1 však io konvertoval kodein (1,5 g/1) se 100% účinností. Tento mikroorganismus byl taxonometricky zařazen a označen jako Rhizobium radiobacter R89-1. Jeho bioehemicko-morfologické zařazení bylo potvrzeno i sekvenční analýzou 16S rDNA. Popsaný bakteriální kmen nepatří mezí taxonometricky popsané kmeny se schopností hydroxylace kodeinu vzorce 1 na 14-hydroxy kodein vzorce 2 a 14-hydroxy kóde ínon vzorce 3.The Rhizobium radiobacter strain R89-1 CCM 7947 was obtained by extensive screening of more than 2000 collection and naturally isolated microorganisms (yeasts, molds and bacteria). Two bacterial strains showing the given properties were screened. However, only strain R89-1 converted codeine (1.5 g / l) with 100% efficiency. This microorganism was classified taxonometrically and designated Rhizobium radiobacter R89-1. Its bioehemic-morphological classification was confirmed by sequence analysis of 16S rDNA. The bacterial strain described does not fall within the taxonometrically described strains with the ability to hydroxylate codeine of formula 1 to 14-hydroxy codeine of formula 2 and 14-hydroxy code of ionon of formula 3.
Předmětem podle lohoto vy nálezu je nový kmen mikroorganismu Rhizobium radiobacter R89-1 CCM 7947, který je schopen hydroxylovat kodein 1The subject of the present invention is a novel strain of the microorganism Rhizobium radiobacter R89-1 CCM 7947 capable of hydroxylating codeine 1.
na 14-hydroxykodein 2 a 14-hydroxykodeinon 3to 14-hydroxycodein 2 and 14-hydroxycodeinone 3
se stoprocentní konverzí kodeinu vzorce 1. Při hydroxylaci vzniká převážně 14-hydroxykodein vzorce 2.The hydroxylation produces predominantly the 14-hydroxycodeine of formula 2.
Výhodou uvedeného procesuje 100% konverze kodeinu při počáteční koncentraci kodeinu 1,5 g/1, 90% při 3,0 g/1 a 47% při 6 g/I. Výhodou konverze daným mikroorganismem je nepřítomnost jo jiných meziproduktů biotransformace.The advantage of said process is 100% conversion of codeine at an initial codeine concentration of 1.5 g / L, 90% at 3.0 g / L and 47% at 6 g / L. The advantage of conversion by a given microorganism is the absence of other biotransformation intermediates.
-3CZ 303607 B6-3GB 303607 B6
Nový mikroorganismus, který je předmětem tohoto vynálezu, je uložen v České sbírce mikroorganismů (Czech Collection of Microorganisms) Masarykovy University v Brně, Tvrdého 14, pod označením CCM 7947.The novel microorganism of the present invention is deposited with the Czech Collection of Microorganisms at Masaryk University in Brno, Tvrdého 14, under the designation CCM 7947.
Vlastnosti kmene jsou uvedeny v Tabulce 1.The strain characteristics are shown in Table 1.
Tabulka 1 Charakteristika kmene Rhizobium radiobacter R89-1 CCM 7947Table 1 Characteristics of Rhizobium radiobacter strain R89-1 CCM 7947
Bylo optimalizováno složení kultivačního média a testován vliv různých zdrojů uhlíku a energie, komplexních komponent médií i různých fyzikálních podmínek kultivace na růst kultury a její schopnost biotransformace kodeinu.The composition of the culture medium was optimized and the influence of various carbon and energy sources, complex media components and various physical conditions of culture on the growth of culture and its ability to codeot biotransformation was tested.
Pokud není uvedeno jinak, byl kmen R89-1 kultivován v třepaných baňkách na komplexním médiu Luria-Bertani (LB) a na médiu doplněném stopovými prvky (médium LBTE), při teplotě až 35 °C a počátečním pH 4 až 9. Složení obou médií je uvedeno v Příkladu 2. Byly vybrány optimální podmínky pro růst buněk, za kterých byl kmen kultivován v míchaném bioreaktoruUnless otherwise noted, strain R89-1 was cultured in shake flasks on Luria-Bertani (LB) complex medium and trace medium supplemented (LBTE medium), at a temperature of up to 35 ° C and an initial pH of 4-9. is shown in Example 2. Optimal conditions for growth of the cells under which the strain was cultured in a stirred bioreactor were selected.
-4CZ 303607 B6 v podmínkách jednorázové nebo přítokované kultivace tak, aby vykazoval schopnost biokonverze kodeinu. Jednorázové kultivace probíhaly bez regulace pH a koncentrace rozpuštěného kyslíku. Přítokované kultivace byly vedeny za regulace pH a koncentrace rozpuštěného kyslíku v médiu. Přítokovaný roztok obsahoval glukózu nebo sacharózu o koncentraci 20 až 50 % hmotn., jako zdroj uhlíku a energie.In a single or fed-batch culture condition, it exhibits the ability of codeine bioconversion. Single cultures were performed without pH regulation and dissolved oxygen concentration. The fed-batch cultures were conducted under control of pH and dissolved oxygen concentration in the medium. The feed solution contained glucose or sucrose at a concentration of 20 to 50 wt% as a source of carbon and energy.
Stanovení stupně konverze bylo provedeno u vzorků kultury za následujících podmínek: odebrané vzorky byly smíchány s terc-butyImethyletherem (TBME) a NH4OH (úprava pH) a látky 1, 2 a 3 byly extrahovány třepáním 20 min při teplotě 28 °C. Pomocí HPLC byla stanovena konverze látky 1 na deriváty 2 a 3.The degree of conversion was determined for the culture samples under the following conditions: the samples taken were mixed with tert-butyl methyl ether (TBME) and NH 4 OH (pH adjustment) and substances 1, 2 and 3 were extracted by shaking for 20 min at 28 ° C. The conversion of compound 1 to derivatives 2 and 3 was determined by HPLC.
Biotransformace morfínu vzorce 4 a thebainu vzorce 5 proběhla za stejných podmínek jako kodeinu s tím rozdílem, že koncentrace morfínu i thebainu byla 0,2 g/1. V 96. hodině byla hodnota konverze morfínu i thebainu 100%.The biotransformation of morphine 4 and thebaine 5 under the same conditions as codeine except that the morphine and thebaine concentrations were 0.2 g / l. At 96 hours, both the morphine and thebaine conversion values were 100%.
Z vlastností kmene CCM 7947, tj. 100% konverze kodeinu vzorce 1 na 14-hydroxykodein vzorce 2 a 14-hydroxykodeinon vzorce 3, vyplývá reálný předpoklad využití předmětného kmene pro hydroxy láci kodeinu vzorce 1, morfínu vzorce 4 a thebainu vzorce 5 za vzniku příslušných 14— hydroxyderivátů ve farmaceutickém průmyslu.The properties of strain CCM 7947, i.e. 100% conversion of codeine of formula 1 to 14-hydroxycodein of formula 2 and 14-hydroxycodeinone of formula 3, suggest a realistic assumption of utilizing the subject strain for hydroxylation of codeine of formula 1, morphine of formula 4 and thebaine of formula 5. 14-hydroxy derivatives in the pharmaceutical industry.
V následujících příkladech je detailně popsán způsob získání kmene Rhizobium radiobacter R89-1, způsob jeho kultivace zaměřený na biotransformační aktivitu kodeinu a optimalizaci pod25 mínek biotransformace, aniž by se jimi omezoval.The following examples describe in detail a method for obtaining a Rhizobium radiobacter R89-1 strain, a method for culturing it, aimed at, but not limited to, biotransformation activity of codeine and optimizing below 25 mins of biotransformation.
Přehled obrázků na výkresechBRIEF DESCRIPTION OF THE DRAWINGS
Obr. 1 Časový průběh koncentrace biomasy (X, ) a biotransformační aktivity (konverze, ♦) v jednorázové kultuře kmene Rhizobium radiobacter R89-1 CCM 7947 na LBTE médiu dle Příkladu 4.Giant. 1 Time course of biomass concentration (X 1) and biotransformation activity (conversion, ♦) in a single culture of Rhizobium radiobacter R89-1 CCM 7947 strain on LBTE medium according to Example 4.
Obr. 2 Časový průběh koncentrace biomasy (X, ) a biotransformační aktivity (konverze, ♦) vjednorázové kultuře kmene Rhizobium radiobacter R89-1 CCM 7947 na LBTE médiu s glukózou (0,5 %) v míchaném bioreaktoru dle Příkladu 5.Giant. 2 Time course of biomass concentration (X 1) and biotransformation activity (conversion, ♦) in a single culture of Rhizobium radiobacter strain R89-1 CCM 7947 on LBTE medium with glucose (0.5%) in a stirred bioreactor according to Example 5.
Obr. 3 Časový průběh koncentrace biomasy (X, ) a biotransformační aktivity (konverze, ♦) v přítokované kultuře (fed batch) kmene Rhizobium radiobacter R89-1 CCM 7947 v míchaném bioreaktoru při kultivační teplotě 30 °C v LBTE médiu s glukózou (1,0 %) dle Příkladu 6.Giant. 3 Time course of biomass concentration (X,) and biotransformation activity (conversion, ♦) in a fed batch of Rhizobium radiobacter strain R89-1 CCM 7947 in a stirred bioreactor at a culture temperature of 30 ° C in LBTE medium with glucose (1.0 %) according to Example 6.
Příklady provedeníExamples
Příklad 1Example 1
Izolace kmene Rhizobium radiobacter R89-1Isolation of Rhizobium radiobacter R89-1
-5CZ 303607 B6-5GB 303607 B6
Kmen Rhizobium radiobacter R89-I byl získán ze zeminy kompostu, kde byly kompostovány zbytky z výroby máku. 10 g zeminy bylo resuspendováno ve 100 ml fyziologického roztoku (9 g/1 NaCl) a třepáno (200 ot/min) po dobu 1 hodiny. Autochtonní mikroflóra byla příslušně naředěna ve fyziologickém roztoku a vyseta na LB agar. Jednotlivé morfologicky odlišné kolonie izolátů, narostlé za 3 dny při 28 °C, byly přeočkovány na čerstvý LB agar a po nárůstu při 28 °C byla u nich stanovena schopnost hydroxylace kodeinu vzorce 1 na 14-OH-kodein vzorce 2 a 14OH-kodeinon vzorce 3 následujícím způsobem: 2 ml LB média doplněné kodeinem v koncentraci 0,1 g/t v 12 jamkových destičkách pro kultivaci (mcwp) byly inokulovány příslušným izolátem a po 72 hodinách kultivace (28 °C a 200 ot./min) bylo k 1 ml vzorku přidáno 0,1 ml NH4OH a 0,5 ml TBME a kultivační kapalina byla extrahována po dobu 20 min. Po odstředění (15 min, 10 000 ot./min) byla organická fáze použita pro kvantitativní stanovení kodeinu vzorce 1,14hydroxy kóde inu vzorce 2 a 14-hydroxykodeinonu vzorce 3 pomocí HPLC za následujících podmínek:The Rhizobium radiobacter R89-I strain was obtained from compost soil where poppy residue was composted. 10 g of soil was resuspended in 100 ml of saline (9 g / l NaCl) and shaken (200 rpm) for 1 hour. The autochthonous microflora was appropriately diluted in saline and plated on LB agar. Individual morphologically different colonies of isolates, grown in 3 days at 28 ° C, were inoculated onto fresh LB agar and, after rising at 28 ° C, were assessed for the ability of hydroxylation of codeine 1 to 14-OH-codeine 2 and 14OH-codeinone 3 ml of LB medium supplemented with codeine at a concentration of 0.1 g / t in 12-well culture plates (mcwp) were inoculated with the appropriate isolate and after 72 hours of culture (28 ° C and 200 rpm) to 1 ml. 0.1 mL of NH 4 OH and 0.5 mL of TBME was added to the sample and the culture liquid was extracted for 20 min. After centrifugation (15 min, 10,000 rpm), the organic phase was used to quantify the codeine of formula 1,14 hydroxy code of formula 2 and 14-hydroxycodeinone of formula 3 by HPLC under the following conditions:
Kolona: C-l 8 Hibar Lichrom manu-fixColumn: C-18 Hibar Lichrom man-fix
Eluční směs: voda+0,1% TFA: MeOH (4:1 V/V)Elution mixture: water + 0.1% TFA: MeOH (4: 1 v / v)
Průtok: 1,3 ml/minFlow rate: 1.3 ml / min
Nanášený objem: 0,05 mlApplication volume: 0.05 ml
Detekce pri vlnové délce: 220 až 214 nmDetection at wavelength: 220 to 214 nm
Teplota kolony: 40 °C Čas analýzy: 5 min Retenční časy:Column temperature: 40 ° C Analysis time: 5 min Retention times:
Látka 1 kodein 2,6 min,Substance 1 codeine 2.6 min,
Látka 2 14-hydroxykodein 2,2 minSubstance 2 14-hydroxycodeine 2.2 min
Látka 3 14-hydroxykodeinon 3,6 minSubstance 3 14-hydroxycodeinone 3.6 min
Z 2000 testovaných izolátů (sbírkové kmeny a izoláty z přírodních materiálů) byly získány 2 bakteriální kmeny vykazující schopnost hydroxylovat sloučeninu vzorce 1 na produkty vzorce 2 a 3. Tyto kmeny byly kultivovány v 50 ml LB média v 500 ml kultivačních baňkách následujícím způsobem: médium bylo inokulováno koloniemi kmenů narostlými na LB agaru a baňky byly inkubovány na rotačním třepacím stroji (200 ot/min, 28 až 30 °C) po dobu 24 hodin (první vegetativní generace), 2 ml narostlé kultury byly použity pro inokulaci třech paralelních baněk s 50 ml LBTE půdy s přídavkem kodeinu v koncentraci 0,1 g/1 (druhá vegetativní generace), které byly kultivovány za stejných podmínek. Po 48 hodinách kultivace (28°C a 200 ot/min) byl vzorek kultury extrahován TBME (viz výše) a organická fáze byla použita pro kvantitativní stanovení biokonverze pomocí HPLC (viz výše). Z obou testovaných kmenů byl vybrán přírodní izolát ze vzorku kompostu s odpady ze zpracování máku, který vykazoval 100% konverzi. Kmen byl označen jako R89-1 a deponován ve sbírce mikroorganismů pod číslem CCM7947.From the 2000 isolates tested (collection strains and isolates from natural materials), 2 bacterial strains were obtained showing the ability to hydroxylate the compound of formula 1 to the products of formulas 2 and 3. These strains were cultured in 50 ml LB medium in 500 ml culture flasks as follows: inoculated with LB agar-colonized strains and the flasks were incubated on a rotary shaker (200 rpm, 28-30 ° C) for 24 hours (first vegetative generation), 2 ml of the grown culture was used to inoculate three parallel 50-well flasks. ml of LBTE broth with the addition of codeine at a concentration of 0.1 g / l (second vegetative generation) which were cultivated under the same conditions. After 48 hours of culture (28 ° C and 200 rpm) the culture sample was extracted with TBME (see above) and the organic phase was used for quantitative determination of bioconversion by HPLC (see above). From both strains tested, a natural isolate was selected from a sample of poppy compost waste, which showed 100% conversion. The strain was designated R89-1 and deposited in the collection of microorganisms under number CCM7947.
Příklad 2Example 2
Optimalizace složení kultivačního média Rhizobium radiobacter R89-1 CCM 7947Optimization of Rhizobium radiobacter R89-1 CCM 7947 culture medium composition
Optimalizace složení média pro růst i konverzi probíhala v 12 jamkových mcwp jak je uvedeno v Příkladu 1.Optimization of the media composition for growth and conversion was performed in 12 well mcwp as shown in Example 1.
Složení kultivačních médií: minerální médium (M9):Composition of culture media: mineral medium (M9):
Na2HPO4 Na 2 HPO 4
KH2PO4 KH 2 PO 4
NaClNaCl
NH4CINH4Cl
MgSO4.7H2O destilovaná vodaMgSO 4 .7H 2 O distilled water
14,6 g/1 3,0 g/1 0,5 g/1 L0 g/1 0,2 g/114.6 g / l 3.0 g / l 0.5 g / l L0 g / l 0.2 g / l
1000 ml zdroje uhlíku a energie:1000 ml carbon and energy source:
glukóza, sacharóza, xylóza, glycerol, sorbitol v koncentracích: 1; 5; 10; 15 a 20 g/l komplexní substráty:glucose, sucrose, xylose, glycerol, sorbitol at concentrations of: 1; 5; 10; 15 and 20 g / l complex substrates:
kaseinový hydrolyzát (CH) 20 a 50 g/l kvasničný extrakt (YE) 20 a 50 g/l trypton (TRY) 20 a 50 g/l ío komplexní médium Luria-Bertani (LB): trypton 10 g/l kvasničný extrakt 5 g/lcasein hydrolyzate (CH) 20 and 50 g / l yeast extract (YE) 20 and 50 g / l trypton (TRY) 20 and 50 g / l 10 Luria-Bertani (LB) complex medium: trypton 10 g / l yeast extract 5 g / l
NaCl 10 g/l destilovaná voda 1000 ml stopové prvky (TE)NaCl 10 g / l distilled water 1000 ml trace elements (TE)
MgSO4.7 H2O 0,2 g/lMgSO 4 .7H 2 O 0.2 g / l
CaCl2.2H2O 50 mg/1CaCl 2 .2H 2 O 50 mg / 1
FeSO4.7 H2O 10 mg/1FeSO 4 .7H 2 O 10 mg / l
Tabulka 2 Vliv média a komplexního zdroje na nárůst (ODóoo) Rhizobium radiobacter R.89-1 CCM 7947 a konverzi kodeinu (0,2 g/l)Table 2 Effect of medium and complex source on Rhizobium radiobacter R.89-1 CCM 7947 increase (OD 600) and codeine conversion (0.2 g / l)
Na základě výsledků uvedených v Tabulce 2 byla pro další optimalizaci vybrána živná půda LB+TE (LTBE). Vliv zdroje uhlíku a energie je uveden v Tabulce 3.Based on the results shown in Table 2, LB + TE (LTBE) broth was selected for further optimization. The effect of carbon and energy sources is shown in Table 3.
Tabulka 3 Vliv zdroje uhlíku a energie na nárůst (OD60o) Rhizobium radiobacter R89-1 CCM 7947 a konverzi kodeinu (0,2 g/l) v médiu LBTETable 3 Effect of carbon source and energy on growth (OD 60 o) of Rhizobium radiobacter R89-1 CCM 7947 and codeine conversion (0.2 g / l) in LBTE medium
-7CZ 303607 B6-7EN 303607 B6
Optimálním zdrojem uhlíku a energie je glukóza a sacharóza v 0,5% koncentraci. Xylóza a sorbitol jsou rovněž použitelným zdrojem uhlíku a energie.Optimal sources of carbon and energy are glucose and sucrose in 0.5% concentration. Xylose and sorbitol are also a useful source of carbon and energy.
Příklad 3 ioExample 3 io
Optimalizace kultivačních podmínek pro Rhizobium radiobacter R89-1 CCM 7947Optimization of culture conditions for Rhizobium radiobacter R89-1 CCM 7947
Vliv pH na růst buněk byl sledován v 12 jamkových mcwp při 29 °C; 2,0 ml LBTE média s příslušným počátečním pH bylo inokulováno 40 μϊ kultury (24 h, 29 °C, LTBE médium příslušného pH). Vliv pH na konverzi kodeinu byl sledován rovněž v 12 jamkových mcwp při 29 °C s tím rozdílem, že byla použita 10% buněčná suspenze připravená následujícím způsobem: kultura narostlá v LBTE (24 h, pH 7,0, 29 °C) byla stočena a resuspendována v čerstvém LBTE médiu s příslušným počátečním pH. Po 48 h konverzi byla stanovena koncentrace 1,2 a 3 jak je uvedeno v Příkladě 1.The effect of pH on cell growth was monitored in 12 well mcwp at 29 ° C; 2.0 ml of LBTE medium with appropriate initial pH was inoculated with 40 μϊ of culture (24 h, 29 ° C, LTBE medium of appropriate pH). The effect of pH on codeine conversion was also monitored in 12 well mcwp at 29 ° C, except that a 10% cell suspension prepared as follows: LBTE grown culture (24 h, pH 7.0, 29 ° C) was centrifuged. and resuspended in fresh LBTE medium at the appropriate initial pH. After 48 h conversion, concentrations of 1.2 and 3 were determined as described in Example 1.
-8CZ 303607 B6-8EN 303607 B6
Tabulka 4 Vliv počáteční hodnoty pH LTBE média na nárůst (OD6<m)) kultury Rhizobium rádiobacter R89-1 CCM 7947 a konverzi kodeinu (0,2 g/1)Table 4 Effect of initial pH of LTBE medium on increase (OD 6 <m) of Rhizobium radiobacter R89-1 CCM 7947 culture and codeine conversion (0.2 g / L)
Vliv teploty na růst buněk byl sledován v 12 jamkových mcwp pri počátečním pH média 7,0: 2,0 ml LBTE média bylo inokulováno 40 μΐ kultuiy narostlé v LTBE médiu (24 h, 29 °C). Vliv io teploty na konverzi kodeinu byl sledován rovněž v 12 jamkových mcwp při počátečním pH média 7,0 s tím rozdílem, že byla použita 10% buněčná suspenze připravená stejně jako při sledování vlivu pH (tento příklad). Po 48. h konverze při různých teplotách byla stanovena koncentrace 1,2 a 3 jak je uvedeno v Příkladě 1.The effect of temperature on cell growth was monitored in 12 well mcwp at an initial pH of 7.0: 2.0 ml of LBTE medium was inoculated with 40 μΐ cultures grown in LTBE medium (24 h, 29 ° C). The effect of temperature on codeine conversion was also observed in 12 well mcwp at an initial pH of 7.0, except that a 10% cell suspension prepared as in pH monitoring (this example) was used. After 48 h conversion at different temperatures, concentrations of 1.2 and 3 were determined as described in Example 1.
Tabulka 4 Vliv teploty na nárůst (ODřoo) kultury Rhizobium radiobacter R89-1 CCM 7947 a konverzi kodeinu (0,2 g/I)Table 4 Effect of temperature on Rhizobium radiobacter R89-1 CCM 7947 growth (ODo) and codeine conversion (0.2 g / L)
Příklad 4Example 4
Jednorázová kultivace kmene Rhizobium radiobacter R89-1 CCM 7947 na LBTE médiu v 25 míchaném bioreaktoruSingle culture of Rhizobium radiobacter R89-1 CCM 7947 strain on LBTE medium in a 25 stirred bioreactor
Jednorázová kultivace na LBTE médiu proběhla v míchaném bioreaktoru Biostat MD: pracovní objem 6 1, vzdušnění 6 1 vzduchu/min, počáteční frekvence míchání 300 ot/min, při teplotě 30 °C a počátečním pH 7,2. Médium bylo inokulováno 5% kulturou druhé generace (víz Příklad 1, s tím rozdílem, že v 500 ml kultivačních baňkách bylo 100 ml LBTE média). pH média a koncentraceSingle cultivation on LBTE medium was performed in a Biostat MD stirred bioreactor: 6 L working volume, 6 L air / min aeration, 300 Rpm stirring start at 30 ° C and an initial pH of 7.2. The medium was inoculated with 5% second generation culture (see Example 1, except that there were 100 ml of LBTE medium in 500 ml culture flasks). pH of medium and concentration
-9CZ 303607 B6 rozpuštěného kyslíku nebyly během kultivace regulovány. V průběhu kultivace v bioreaktoru byly v pravidelných časových intervalech odebírány vzorky kultury a stanovena koncentrace biomasy (suchá hmotnost buněk, X) a schopnost buněk hydroxylovat kodein vzorce 1 na 14OH-kodein vzorce 2 a 14-OH-kodeinon vzorce 3 (buněčný pelet ze 2 ml kultivační kapaliny byl uschován při -30 °C; po skončení kultivace byly všechny vzorky resuspendovány ve 2 ml LBTE média s kodeinem v koncentraci 0,2 g/1 a po 48 h konverze stanovena koncentrace látky vzorce 1, 2 a 3 jak je uvedeno v Příkladě 1). Maximální koncentrace suché hmotnosti biomasy (1,7 g/1) bylo dosaženo v 16. hodině kultivace, maximální konverze látky vzorce 1 (82%) až na konci kultivace (25. hodina). Časový průběh koncentrace biomasy (X, ) a biotransformační aktivity je io uveden v Obr. 1.The dissolved oxygen was not regulated during cultivation. During culture in the bioreactor, culture samples were taken at regular time intervals and the biomass concentration (dry cell weight, X) and the ability of the cells to hydroxylate codeine of formula 1 to 14OH-codeine of formula 2 and 14-OH-codeinone of formula 3 were determined. ml of culture liquid was stored at -30 [deg.] C. after completion of the culture all samples were resuspended in 2 ml of LBTE medium with codeine at a concentration of 0.2 g / l and after 48 h conversion the concentration of the compound of formula 1, 2 and 3 was determined. in Example 1). The maximum dry mass concentration of biomass (1.7 g / l) was reached at 16 hours of cultivation, maximum conversion of compound of formula 1 (82%) only at the end of cultivation (25 hours). The time course of biomass concentration (X 1) and biotransformation activity is also shown in Fig. 2. 1.
Příklad 5Example 5
Jednorázová kultivace kmene Rhizobium radiobacter R89-1 CCM 7947 na LTBE médiu s glukózou v míchaném bioreactoru.Single culture of Rhizobium radiobacter R89-1 CCM 7947 strain on LTBE medium with glucose in a stirred bioreactor.
Jednorázová kultivace proběhla za stejných podmínek jako v Příkladu 4 s tím rozdílem, že do média byla na počátku kultivace přidána glukóza v koncentraci 0,5 %. Maximální koncentrace suché hmotnosti biomasy (5,7 g/1) bylo dosaženo v 16. hodině, maximální konverze látky 1 (100%) v 18. hodině kultivace. Časový průběh koncentrace biomasy (X, ) a biotransformační aktivity (konverze, ♦) v míchaném bioreaktoru je uveden v Obr. 2.A single culture was performed under the same conditions as in Example 4 except that glucose at a concentration of 0.5% was added to the medium at the beginning of the culture. The maximum dry mass concentration of biomass (5.7 g / l) was achieved at 4 pm, the maximum conversion of compound 1 (100%) at 18 hours of culture. The time course of biomass concentration (X 1) and biotransformation activity (conversion, ♦) in the stirred bioreactor is shown in Fig. 2. 2.
Příklad 6Example 6
Přítokovaná (fed-batch, 40% roztok glukózy) kultivace Rhizobium radiobacter R89-1 CCM 7947 na LTBE médiu s glukózou v míchaném bioreaktoruFed-batch (40% glucose solution) culture of Rhizobium radiobacter R89-1 CCM 7947 on LTBE medium with glucose in a stirred bioreactor
Přítokovaná kultivace proběhla za stejných podmínek jako v Příkladu 5 s tím rozdílem, že počáteční koncentrace glukózy byla 1,0% a od 13. hodiny do 22. hodiny kultivace byl do reaktoru přidáván 40% roztok glukózy tak, aby byla udržována koncentrace rozpuštěného kyslíku v médiu (pO2) v rozmezí 25 až 35 % hodnoty maximálního nasycení média kyslíkem. Hodnota pH byla regulována čpavkem na hodnotu pH = 7,5. Obr. 3 uvádí časový průběh koncentrace biomasy a biotransformační aktivity. Za tohoto režimu kultivace bylo dosaženo maximální koncentrace suché hmotnosti biomasy (11,9 g/1) i maximální konverze látky vzorce 1 (100%) ve 20. hodině kultivace.The fed-batch cultivation was carried out under the same conditions as in Example 5 except that the initial glucose concentration was 1.0% and from 1pm to 10pm a 40% glucose solution was added to the reactor to maintain dissolved oxygen concentration in the reactor. medium (pO 2 ) ranging from 25 to 35% of the maximum oxygen saturation value of the medium. The pH was controlled with ammonia to pH = 7.5. Giant. 3 shows the time course of biomass concentration and biotransformation activity. Under this cultivation regimen, both the maximum biomass dry weight concentration (11.9 g / L) and the maximum conversion of the compound of Formula 1 (100%) at 20 hours of culture were achieved.
Příklad 7Example 7
Vliv počáteční koncentrace kodeinu l na jeho biotransformaci 10% buněčnou suspenzíEffect of initial concentration of codeine 1 on its biotransformation by 10% cell suspension
Buňky z konce kultivace uvedené v Příkladu 6 byly stočeny, promyty fyziologickým roztokem a 45 resuspendovány do LBTE média tak, aby výsledná koncentrace buněk byla 10% (vlhká hmotnost buněk). Biotransformace byly prováděny v 500 ml kultivačních baňkách s 50 ml buněčné suspenze na rotační třepačce při 200 ot/min a 29 °C. Výchozí koncentrace substrátu 1 byla 0,2 ažThe cells from the end of the culture described in Example 6 were centrifuged, washed with saline, and resuspended in LBTE medium to a final cell concentration of 10% (wet cell weight). Biotransformations were performed in 500 ml culture flasks with 50 ml cell suspension on a rotary shaker at 200 rpm and 29 ° C. The initial substrate 1 concentration was 0.2 to 0.2
6,0 g/1.6.0 g / l.
- 10CZ 303607 B6- 10GB 303607 B6
Příklad 8Example 8
Vliv počáteční koncentrace kóde inu 1 na jeho biotransformaci 20% buněčnou suspenziInfluence of initial concentration of code 1 in on its biotransformation by 20% cell suspension
Biokonverze probíhala za stejných podmínek jako v Příkladu 7 s tím rozdílem, že výsledná koncentrace buněk byla 20 % (vlhká hmotnost buněk) a koncentrace výchozí látky vzorce 1 1,5; 3 to nebo 6 g/1.The bioconversion was carried out under the same conditions as in Example 7 except that the final cell concentration was 20% (wet cell weight) and the starting compound of Formula 1 was 1.5; 3 to or 6 g / l.
is Příklad 9is Example 9
Biotransformace morflniu a thebainu 20% buněčnou suspenzíBiotransformation of morphine and thebaine by 20% cell suspension
Biotransformace morfinu vzorce 4 a thebainu vzorce 5 proběhla za stejných podmínek jako 20 v Příkladu 8 s tím rozdílem, že koncentrace morfinu i thebainu byla 0,2 g/1. V 96. hodině byla hodnota konverze morfinu i thebainu 100%.The biotransformation of morphine 4 and thebaine 5 under the same conditions as 20 in Example 8 except that the concentration of both morphine and thebaine was 0.2 g / l. At 96 hours, both the morphine and thebaine conversion values were 100%.
Claims (7)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20110761A CZ303607B6 (en) | 2011-11-23 | 2011-11-23 | Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone |
| PCT/CZ2012/000116 WO2013075676A1 (en) | 2011-11-23 | 2012-11-19 | Microorganism strain rhizobium radiobacter r89-1 ccm 7947 hydroxylating codeine to 14-oh-codeine and 14-oh-codeinone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20110761A CZ303607B6 (en) | 2011-11-23 | 2011-11-23 | Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ2011761A3 CZ2011761A3 (en) | 2013-01-02 |
| CZ303607B6 true CZ303607B6 (en) | 2013-01-02 |
Family
ID=47351334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20110761A CZ303607B6 (en) | 2011-11-23 | 2011-11-23 | Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone |
Country Status (2)
| Country | Link |
|---|---|
| CZ (1) | CZ303607B6 (en) |
| WO (1) | WO2013075676A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304116B6 (en) * | 2012-09-13 | 2013-10-30 | Zentiva, K.S. | Codeine hydroxylation using the strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110272848B (en) * | 2019-07-10 | 2023-01-03 | 西北农林科技大学 | Rhizobium J16 with potassium-dissolving effect and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798792A (en) * | 1985-09-09 | 1989-01-17 | E. I. Du Pont De Nemours And Company | Bacterial hydroxylation of codeine |
-
2011
- 2011-11-23 CZ CZ20110761A patent/CZ303607B6/en not_active IP Right Cessation
-
2012
- 2012-11-19 WO PCT/CZ2012/000116 patent/WO2013075676A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798792A (en) * | 1985-09-09 | 1989-01-17 | E. I. Du Pont De Nemours And Company | Bacterial hydroxylation of codeine |
Non-Patent Citations (4)
| Title |
|---|
| Iizuka K et al. Studies in the field of microbiological decomposition. XVI. Decomposition of alkaloids of the morphine group by Trametes sanguinea. Chemical & Pharmaceutical Bulletin, 1962, 10(1), 67-70. * |
| Liras P et al. Enzymatic transformation of morphine by hydroxysteroid dehydrogenase from Pseudomonas testosteroni. Applied Microbiology, 1975, 30(4), 650-656. * |
| Liras P, Umbreit WW. Transformation of morphine by resting cells and cell-free systems of Arthrobacter sp. Applied Microbiology, 1975, 30(2), 262-266. * |
| Lister DL et al. Transformations of codeine to important semisynthetic opiate derivatives by Pseudomonas putida m10. FEMS Microbiology Letters, 1999, 181, 137-144. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304116B6 (en) * | 2012-09-13 | 2013-10-30 | Zentiva, K.S. | Codeine hydroxylation using the strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013075676A1 (en) | 2013-05-30 |
| CZ2011761A3 (en) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017001677A1 (en) | Use of microbacterium strains for the production of antibacterial agents | |
| JP2002535977A5 (en) | ||
| CN101402929A (en) | A alkali-fast sorangium cellulosum and uses of the same in producing epothilone | |
| CN107868757B (en) | Endophytic fungi and application thereof | |
| Kyslíková et al. | Biotransformation of codeine to 14-OH-codeine derivatives by Rhizobium radiobacter R89-1 | |
| CZ303607B6 (en) | Codeine-hydrolyzing strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism to 14-OH-codeine and 14-OH-codeinone | |
| US9365880B2 (en) | Fermentation process for the production of rapamycin | |
| CN102382780A (en) | Microbacterium oxydans and method for preparing chiral bis(trifluoromethyl) phenyl ethanol by using same | |
| WO2008005381A2 (en) | Process for the preparation of moxidectin comprising a step of microbiologically mediated oxidation of 23 -hydroxy- ll- f28249 -alpha to 23-keto-ll-f28249-alpha | |
| CZ304116B6 (en) | Codeine hydroxylation using the strain of Rhizobium radiobacter R89-1 CCM 7947 microorganism | |
| CN102952761B (en) | Nocardia strain capable of converting quinine into (R)-3-quinine alcohol and transformation method | |
| CN1189568C (en) | Biotransfer process for preparing artemisine compounds | |
| CZ2016482A3 (en) | Strain of the microorganism Raoultella sp. KDF8 CCM 8678 degrading active pharmaceutical ingredients from the following group: diclofenac, codeine, ibuprofen and ketoprofen | |
| US3994781A (en) | Process for the production of protein | |
| JP6799290B2 (en) | Microorganisms capable of decomposing alkylene glycol monoalkyl ethers and their use | |
| CN102952760B (en) | A strain of Rhodococcus erythropolis capable of converting quinine into (S)-3-quinine alcohol and its transformation method | |
| CN113337433B (en) | Pseudomonas capable of producing pyrroloquinoline quinone and application thereof | |
| JP4439079B2 (en) | Method for producing pravastatin | |
| AU620595B2 (en) | Process for the preparation of macrolide compounds | |
| JP6201120B2 (en) | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid | |
| JP5693052B2 (en) | Sugar derivative and method for producing the same | |
| JP4449015B2 (en) | Process for producing cyclosporine derivatives | |
| JPH0378106B2 (en) | ||
| JP5333966B2 (en) | Method for producing (S) -3-quinuclidinol | |
| CN112574933A (en) | Strain for producing reductive dehalogenase and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20151123 |